Lycia Therapeutics, Inc.: CBO Touami Sofia received 68,755 shares

What happened

• Touami Sofia, chief business officer, received 68,755 shares as a derivative award (stock options) on Aug 11, 2026, acquired at $0.00 per share (transaction code A), total reported value $0.

Key details

• Transaction date and price: Aug 11, 2026 at $0.00 (derivative grant, code A).
• Shares owned after the transaction: not specified in the filing.
• Footnotes: F1 — the transaction occurred prior to the issuer's registration of a class of equity securities and is reported under Rule 16a-2(a); F2 — the options vest 1/48 of the total award monthly over 4 years, with the first tranche vested on Sep 6, 2026, subject to continued service.
• Filing date: Oct 26, 2026 (reporting the Aug 11, 2026 transaction under Rule 16a-2(a)).

Why it may matter

• This was a derivative grant of options, not a market purchase or sale.
• The award vests over time (1/48 monthly over 4 years), with the first tranche vested on Sep 6, 2026.
• A filing does not show why the insider traded or why the company acted.